| Scenario . | Difference in cost (€) . | Difference in effect (QALYs) . | ICER €/QALY (95% CI) . |
|---|---|---|---|
| Main analysis (lifetime timeframe) | 8 524 | 1.41 | 6 045 (4 292–9 411) |
| Costs and health effects undiscounted (lifetime timeframe) | 11 774 | 2.44 | 4 825 (3 320 –7 958) |
| Costs and health effects discounted at 5% (lifetime timeframe) | 11 911 | 1.02 | 11 677 (8 181–17 697) |
| Health effects undiscounted, costs discounted at 3% (lifetime timeframe) | 12 023 | 2.45 | 4 907 (3 437–8 187) |
| Same mortality rate in CRT and control groups assumed between end of trial and 6 years (6 year time frame) | 1 986 | 0.43 | 4 619 (2 163–10 602) |
| Different mortality rates in CRT and control groups assumed between end of trial and 6 years (6 year time frame) | 1 977 | 0.52 | 3 802 (1 895–7 368) |
| Same mortality rate in CRT and control groups assumed from the end of trial and onwards (lifetime timeframe) | 1 972 | 0.70 | 2 817 (1 179–9 799) |
| Device longevity 5 years (lifetime timeframe) | 9 450 | 1.41 | 6 702 (4 820–10 642) |
| Device longevity 7 years (lifetime timeframe) | 7 536 | 1.41 | 5 345 (3 795–8 378) |
| Hellenic NHS perspective | 8 275 | 1.41 | 5 869 (4 193–9 162) |
| Private health-care perspective | 9 186 | 1.41 | 6 515 (4 725–10 202) |
| CRT with defibrillation back-up (CRT-D) | 24 949 | 2.10 | 11 880 (9 479–16 076) |
| Scenario . | Difference in cost (€) . | Difference in effect (QALYs) . | ICER €/QALY (95% CI) . |
|---|---|---|---|
| Main analysis (lifetime timeframe) | 8 524 | 1.41 | 6 045 (4 292–9 411) |
| Costs and health effects undiscounted (lifetime timeframe) | 11 774 | 2.44 | 4 825 (3 320 –7 958) |
| Costs and health effects discounted at 5% (lifetime timeframe) | 11 911 | 1.02 | 11 677 (8 181–17 697) |
| Health effects undiscounted, costs discounted at 3% (lifetime timeframe) | 12 023 | 2.45 | 4 907 (3 437–8 187) |
| Same mortality rate in CRT and control groups assumed between end of trial and 6 years (6 year time frame) | 1 986 | 0.43 | 4 619 (2 163–10 602) |
| Different mortality rates in CRT and control groups assumed between end of trial and 6 years (6 year time frame) | 1 977 | 0.52 | 3 802 (1 895–7 368) |
| Same mortality rate in CRT and control groups assumed from the end of trial and onwards (lifetime timeframe) | 1 972 | 0.70 | 2 817 (1 179–9 799) |
| Device longevity 5 years (lifetime timeframe) | 9 450 | 1.41 | 6 702 (4 820–10 642) |
| Device longevity 7 years (lifetime timeframe) | 7 536 | 1.41 | 5 345 (3 795–8 378) |
| Hellenic NHS perspective | 8 275 | 1.41 | 5 869 (4 193–9 162) |
| Private health-care perspective | 9 186 | 1.41 | 6 515 (4 725–10 202) |
| CRT with defibrillation back-up (CRT-D) | 24 949 | 2.10 | 11 880 (9 479–16 076) |
Mean incremental cost-effectiveness ratio (95% confidence interval). Costs in €.
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; CRT, cardiac resynchronization therapy; NHS, National Health Service.
| Scenario . | Difference in cost (€) . | Difference in effect (QALYs) . | ICER €/QALY (95% CI) . |
|---|---|---|---|
| Main analysis (lifetime timeframe) | 8 524 | 1.41 | 6 045 (4 292–9 411) |
| Costs and health effects undiscounted (lifetime timeframe) | 11 774 | 2.44 | 4 825 (3 320 –7 958) |
| Costs and health effects discounted at 5% (lifetime timeframe) | 11 911 | 1.02 | 11 677 (8 181–17 697) |
| Health effects undiscounted, costs discounted at 3% (lifetime timeframe) | 12 023 | 2.45 | 4 907 (3 437–8 187) |
| Same mortality rate in CRT and control groups assumed between end of trial and 6 years (6 year time frame) | 1 986 | 0.43 | 4 619 (2 163–10 602) |
| Different mortality rates in CRT and control groups assumed between end of trial and 6 years (6 year time frame) | 1 977 | 0.52 | 3 802 (1 895–7 368) |
| Same mortality rate in CRT and control groups assumed from the end of trial and onwards (lifetime timeframe) | 1 972 | 0.70 | 2 817 (1 179–9 799) |
| Device longevity 5 years (lifetime timeframe) | 9 450 | 1.41 | 6 702 (4 820–10 642) |
| Device longevity 7 years (lifetime timeframe) | 7 536 | 1.41 | 5 345 (3 795–8 378) |
| Hellenic NHS perspective | 8 275 | 1.41 | 5 869 (4 193–9 162) |
| Private health-care perspective | 9 186 | 1.41 | 6 515 (4 725–10 202) |
| CRT with defibrillation back-up (CRT-D) | 24 949 | 2.10 | 11 880 (9 479–16 076) |
| Scenario . | Difference in cost (€) . | Difference in effect (QALYs) . | ICER €/QALY (95% CI) . |
|---|---|---|---|
| Main analysis (lifetime timeframe) | 8 524 | 1.41 | 6 045 (4 292–9 411) |
| Costs and health effects undiscounted (lifetime timeframe) | 11 774 | 2.44 | 4 825 (3 320 –7 958) |
| Costs and health effects discounted at 5% (lifetime timeframe) | 11 911 | 1.02 | 11 677 (8 181–17 697) |
| Health effects undiscounted, costs discounted at 3% (lifetime timeframe) | 12 023 | 2.45 | 4 907 (3 437–8 187) |
| Same mortality rate in CRT and control groups assumed between end of trial and 6 years (6 year time frame) | 1 986 | 0.43 | 4 619 (2 163–10 602) |
| Different mortality rates in CRT and control groups assumed between end of trial and 6 years (6 year time frame) | 1 977 | 0.52 | 3 802 (1 895–7 368) |
| Same mortality rate in CRT and control groups assumed from the end of trial and onwards (lifetime timeframe) | 1 972 | 0.70 | 2 817 (1 179–9 799) |
| Device longevity 5 years (lifetime timeframe) | 9 450 | 1.41 | 6 702 (4 820–10 642) |
| Device longevity 7 years (lifetime timeframe) | 7 536 | 1.41 | 5 345 (3 795–8 378) |
| Hellenic NHS perspective | 8 275 | 1.41 | 5 869 (4 193–9 162) |
| Private health-care perspective | 9 186 | 1.41 | 6 515 (4 725–10 202) |
| CRT with defibrillation back-up (CRT-D) | 24 949 | 2.10 | 11 880 (9 479–16 076) |
Mean incremental cost-effectiveness ratio (95% confidence interval). Costs in €.
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; CRT, cardiac resynchronization therapy; NHS, National Health Service.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
